CDH1 and central nervous system cancer: Taken together, the frequency of rare non-silent CDH1 germline variants predicted to be deleterious was significantly increased in our cohort of glioma families (2/15, 13.3%) compared to controls from the gnomAD v2.1.1 dataset (1.7%) (Table 1).